Non-small Cell Lung Cancer

Phase 3 study comparing niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy for patients that have remained stable or responded to first line platinum based chemo plus pembrolizumab for stage IIIB or IV non-small cell lung cancer (NSCLC).